Clinical Trial Update: Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

View source ↗

Summary

A clinical trial status update indicating recruitment for a study combining TACE, TKIs/anti-VEGF therapy, and immune checkpoint inhibitors as conversion therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Tongji Hospital | Conditions: Hepatocellular Carcinoma Non-resectable | Status: RECRUITING